Literature DB >> 35899236

PRO: Should patients with nonalcoholic steatohepatitis fibrosis undergo bariatric surgery as primary treatment?

Nayantara Orekondy1, David Lee2, Raza Malik1.   

Abstract

Content available: Audio Recording.
© 2022 American Association for the Study of Liver Diseases.

Entities:  

Year:  2022        PMID： 35899236      PMCID： PMC9306429          DOI： 10.1002/cld.1224

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


  20 in total

1.  Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis.

Authors:  Guillaume Lassailly; Robert Caiazzo; Line-Carolle Ntandja-Wandji; Viviane Gnemmi; Gregory Baud; Helene Verkindt; Massih Ningarhari; Alexandre Louvet; Emmanuelle Leteurtre; Violeta Raverdy; Sébastien Dharancy; François Pattou; Philippe Mathurin
Journal:  Gastroenterology       Date:  2020-06-15       Impact factor: 22.682

Review 2.  Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.

Authors:  G Musso; M Cassader; F Rosina; R Gambino
Journal:  Diabetologia       Date:  2012-01-27       Impact factor: 10.122

3.  Influence of Liver Disease on Perioperative Outcome After Bariatric Surgery in a Northern German Cohort.

Authors:  Stefan Wolter; Anna Duprée; Christina Coelius; Alexander El Gammal; Johannes Kluwe; Nina Sauer; Oliver Mann
Journal:  Obes Surg       Date:  2017-01       Impact factor: 4.129

Review 4.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

5.  Safety and efficacy of bariatric surgery in patients with advanced fibrosis.

Authors:  T Singh; G S Kochhar; G B Goh; P Schauer; S Brethauer; M Kroh; A Aminian; R Lopez; S Dasarathy; A J McCullough
Journal:  Int J Obes (Lond)       Date:  2016-11-24       Impact factor: 5.095

6.  Safety of metabolic and bariatric surgery in obese patients with liver cirrhosis: a systematic review and meta-analysis.

Authors:  Lokesh Agarwal; Ankit Kumar Sahu; Aditya Baksi; Ayushi Agarwal; Sandeep Aggarwal
Journal:  Surg Obes Relat Dis       Date:  2020-11-13       Impact factor: 4.734

7.  Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients.

Authors:  Guillaume Lassailly; Robert Caiazzo; David Buob; Marie Pigeyre; Hélène Verkindt; Julien Labreuche; Violeta Raverdy; Emmanuelle Leteurtre; Sébastien Dharancy; Alexandre Louvet; Monique Romon; Alain Duhamel; François Pattou; Philippe Mathurin
Journal:  Gastroenterology       Date:  2015-04-25       Impact factor: 22.682

8.  Long-term Results of Bariatric Surgery for Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis Treatment in Morbidly Obese Japanese Patients.

Authors:  Daisuke Uehara; Yosuke Seki; Satoru Kakizaki; Norio Horiguchi; Hiroki Tojima; Yuichi Yamazaki; Ken Sato; Masanobu Yamada; Toshio Uraoka; Kazunori Kasama
Journal:  Obes Surg       Date:  2019-04       Impact factor: 4.129

9.  Histological grading evaluation of non-alcoholic fatty liver disease after bariatric surgery: a retrospective and longitudinal observational cohort study.

Authors:  Felipe David Mendonça Chaim; Lívia Bitencourt Pascoal; Elinton Adami Chaim; Raquel Franco Leal; Fábio Henrique Mendonça Chaim; Bruna Biazon Palma; Tiago Andrade Damázio; Larissa Bastos Eloy da Costa; Rita Carvalho; Everton Cazzo; Martinho Antônio Gestic; Murillo Pimentel Utrini; Marciane Milanski
Journal:  Sci Rep       Date:  2020-05-22       Impact factor: 4.379

10.  Weight loss intervention adherence and factors promoting adherence: a meta-analysis.

Authors:  Mark Lemstra; Yelena Bird; Chijioke Nwankwo; Marla Rogers; John Moraros
Journal:  Patient Prefer Adherence       Date:  2016-08-12       Impact factor: 2.711
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.